Wave Life Sciences reports Q4 EPS (47c), consensus (41c)

Reports Q4 revenue $1.24M, consensus $7.06M. "2022 was a transformational year that positioned Wave to become the leading RNA medicines company. We achieved clinical validation of our PRISM platform, demonstrating target engagement in all three of our clinical programs and translation of our preclinical data to the clinic. We maintained our leadership in RNA editing by achieving the first RNA editing clinical candidate, WVE-006, which is a potentially comprehensive approach for treating alpha-1 antitrypsin deficiency. In December 2022, we entered into a strategic collaboration with GSK that we expect will continue to grow our pipeline with first-in-class candidates, further unlock our RNA editing and other platform capabilities, maximize commercial potential for WVE-006, and bring additional cash onto our balance sheet through research funding and potential collaboration milestones," said Paul Bolno, MD, MBA, President and Chief Executive Officer of Wave Life Sciences. "In 2023, we are poised to deliver the first RNA editing candidate to the clinic, which will be an exciting moment not just for Wave, but for the entire nucleic acids field. We are initiating Part B of the WVE-N531 study in Duchenne muscular dystrophy to assess dystrophin after 24 and 48 weeks of biweekly dosing, with potential for this program to become a significant commercial opportunity for Wave. We’re also on track for new clinical data from our HD and ALS/FTD programs. Beyond our ongoing clinical activities, we are driving forward the next wave of first- or best-in-class programs that expand our pipeline, and we expect to announce new wholly owned RNA editing programs and preclinical data this year."